Background
Methods
Ethical considerations
Study design
Case definitions for dengue
RT-PCR
Serology for dengue viral infection
Measurement of peripheral venous lactate
Sample size calculation
Statistical analysis
Results
Patient characteristics
Comparison of clinical and laboratory characteristics of patients with severe and non-severe dengue
Characteristics | All dengue cases | The 2009 WHO dengue case definitions |
p-value | ||||
---|---|---|---|---|---|---|---|
Severe dengue | Non-severe dengue | ||||||
n | No. (%) | n | No. (%) | n | No. (%) | ||
Baseline characteristics | |||||||
Age (years), median (IQR) | 125 | 24.0 (19.0–36.0) | 20 | 36.5 (20.2–50.5) | 105 | 23.0 (19.0–33.5) | 0.010c
|
Sex, female | 125 | 57 (45.6) | 20 | 11 (55.0) | 105 | 46 (43.8) | 0.499a
|
Residential area, Bangkok | 125 | 104 (83.2) | 20 | 18 (90.0) | 105 | 86 (81.9) | 0.523b
|
Clinical symptoms | |||||||
Fever (days), median (IQR) | 125 | 4.0 (3.0–5.0) | 20 | 5.0 (4.0–6.0) | 105 | 4.0 (3.0–5.0) | 0.003c
|
Myalgia | 125 | 114 (91.2) | 20 | 19 (95.0) | 105 | 95 (90.5) | 1.000b
|
Headache | 125 | 109 (87.2) | 20 | 17 (85.0) | 105 | 92 (87.6) | 0.720b
|
Lethargy | 125 | 94 (75.2) | 20 | 18 (90.0) | 105 | 76 (72.4) | 0.155b
|
Nausea | 125 | 88 (70.4) | 20 | 14 (70.0) | 105 | 74 (70.5) | 1.000a
|
Retro-orbital pain | 125 | 80 (64.0) | 20 | 11 (55.0) | 105 | 69 (65.7) | 0.509a
|
Abdominal pain | 125 | 53 (42.4) | 20 | 9 (45.0) | 105 | 44 (41.9) | 0.992a
|
Arthralgia | 125 | 41 (32.8) | 20 | 9 (45.0) | 105 | 32 (30.5) | 0.313a
|
Persistent vomiting | 125 | 20 (16.0) | 20 | 8 (40.0) | 105 | 12 (11.4) | 0.004b
|
Physical examinations | |||||||
Temperature (°C), median (IQR) | 125 | 38.5 (37.8–39.2) | 20 | 38.5 (37.7–39.0) | 105 | 38.5 (37.8–39.2) | 0.580c
|
Mean arterial pressure (mmHg), median (IQR) | 125 | 86 (78–92) | 20 | 84 (70–93) | 105 | 86 (78–92) | 0.522c
|
Heart rate (beats/min), median (IQR) | 125 | 80 (66–90) | 20 | 83 (70–91) | 105 | 79 (66–90) | 0.457c
|
Respiratory rate (breaths/min), median (IQR) | 125 | 22 (20–22) | 20 | 22 (20–24) | 105 | 20 (18–22) | 0.019c
|
Tourniquet test, positive | 125 | 106 (84.8) | 20 | 15 (75.0) | 105 | 91 (86.7) | 0.187b
|
Rash | 125 | 55 (44.0) | 20 | 9 (45.0) | 105 | 46 (43.8) | 1.000a
|
Mucosal bleeding | 125 | 53 (42.4) | 20 | 14 (70.0) | 105 | 39 (37.1) | 0.013a
|
Skin bleeding | 125 | 35 (28.0) | 20 | 13 (65.0) | 105 | 22 (21.0) | <0.001a
|
Liver span of >15 cm | 125 | 29 (23.2) | 20 | 12 (60.0) | 105 | 17 (16.2) | <0.001b
|
Clinical fluid accumulation | 125 | 25 (20.0) | 20 | 15 (75.0) | 105 | 10 (9.5) | <0.001b
|
Confirmation tests for dengue | |||||||
Dengue RT-PCR, positive | 125 | 79 (63.2) | 20 | 15 (75.0) | 105 | 64 (61.0) | 1.000b
|
Serotypes 1 or 4 | 79 | 22 (27.8) | 15 | 4 (26.7) | 64 | 18 (28.1) | |
Serotypes 2 or 3 | 79 | 57 (72.2) | 15 | 11 (73.3) | 64 | 46 (71.9) | |
Dengue ELISA, positive | 125 | 119 (95.2) | 20 | 20 (100) | 105 | 99 (94.3) | 0.526b
|
Primary dengue infection | 119 | 4 (3.4) | 20 | 1 (5.0) | 99 | 3 (3.0) | |
Secondary dengue infection | 119 | 115 (96.6) | 20 | 19 (95.0) | 99 | 96 (97.0) | |
Complete blood counts | |||||||
Hemoglobin, median (IQR), g/dL | 125 | 13.8 (12.8–14.9) | 20 | 13.9 (12.7–16.7) | 105 | 13.8 (12.8–14.9) | 0.540c
|
Hematocrit, median (IQR), % | 125 | 41.6 (38.1–44.4) | 20 | 40.7 (37.1–48.9) | 105 | 41.6 (38.4–44.4) | 0.882c
|
WBC, median (IQR), ×103/μL | 125 | 3.0 (2.2–4.8) | 20 | 3.6 (2.1–6.8) | 105 | 3.0 (2.2–4.6) | 0.324c
|
Platelet counts, median (IQR), ×103/μL | 125 | 78.0 (48.0–127.0) | 20 | 41.5 (11.2–63.5) | 105 | 90.0 (56.0–145.5) | <0.001c
|
Blood biochemistry | |||||||
Creatinine, median (IQR), mg/dL | 125 | 0.8 (0.6–1.0) | 20 | 0.8 (0.6–1.1) | 105 | 0.9 (0.7–1.0) | 0.859c
|
Albumin, median (IQR), g/dL | 125 | 4.2 (3.9–4.5) | 20 | 3.6 (3.1–4.2) | 105 | 4.3 (4.0–4.5) | <0.001c
|
AST, median (IQR), IU/L | 125 | 94 (38–202) | 20 | 228 (162–760) | 105 | 71 (36–156) | <0.001c
|
ALT, median (IQR), IU/L | 125 | 65 (22–148) | 20 | 172 (114–415) | 105 | 46 (18–102) | <0.001c
|
Lactate level, median (IQR), mmol/L | 125 | 1.5 (1.2–1.9) | 20 | 2.7 (1.8–3.1) | 105 | 1.4 (1.2–1.8) | <0.001c
|
Duration of hospitalization (days), median (IQR) | 125 | 3.9 (2.8–5.0) | 20 | 4.8 (2.9–9.8) | 105 | 3.7 (2.7–4.9) | 0.012c
|
Diagnostic value of the 2009 WHO warning signs for identifying severe dengue
The 2009 WHO definitions | Sensitivity (95 % CI) | Specificity (95 % CI) | PPV (95 % CI) | NPV (95 % CI) | LR+ (95 % CI) | LR– (95 % CI) | ||
---|---|---|---|---|---|---|---|---|
Severe (n = 20) | Non-severe (n = 105) | |||||||
Individual warning sign | ||||||||
Abdominal pain | 9 | 44 | 45.0 (23.1–68.5) | 58.1 (48.1–67.7) | 17.0 (8.1–29.8) | 84.7 (74.3–92.1) | 1.1 (0.6–1.8) | 0.9 (0.6–1.4) |
Persistent vomiting | 8 | 12 | 40.0 (19.1–64.0) | 88.6 (80.9–94.0) | 40.0 (19.1–64.0) | 88.6 (80.9–94.0) | 3.5 (1.6–7.4) | 0.7 (0.5–1.0) |
Clinical fluid accumulation | 15 | 10 | 75.0 (50.9–91.3) | 90.5 (83.2–95.3) | 60.0 (38.7–78.9) | 95.0 (88.7–98.4) | 7.9 (4.2–15.0) | 0.3 (0.1–0.6) |
Lethargy | 18 | 76 | 90.0 (68.3–98.8) | 27.6 (19.3–37.2) | 19.2 (11.8–28.6) | 93.6 (78.6–99.2) | 1.2 (1.0–1.5) | 0.4 (0.1–1.4) |
Liver span of >15 cm | 12 | 17 | 60.0 (36.0–80.9) | 83.8 (75.4–90.3) | 41.4 (23.5–61.1) | 91.7 (84.2–96.3) | 3.7 (2.1–6.5) | 0.5 (0.3–0.8) |
Mucosal bleeding | 14 | 39 | 70.0 (45.7–88.1) | 62.9 (52.9–72.1) | 26.4 (15.3–40.3) | 91.7 (82.7–96.9) | 1.9 (1.3–2.8) | 0.5 (0.2–1.0) |
Hematocrit >2 % and platelets ≤100 × 103/μL | 12 | 42 | 60.0 (36.0–80.9) | 60.0 (50.0–69.4) | 22.2 (12.0–35.6) | 88.7 (79.0–95.0) | 1.5 (1.0–2.3) | 0.7 (0.4–1.2) |
Number of warning signs | ||||||||
≥ 1 | 20 | 95 | 100.0 (83.2–100.0) | 9.5 (4.7–16.8) | 17.4 (11.0–25.6) | 100.0 (69.2–100.0) | 1.1 (1.0–1.2) | 0 |
≥ 2 | 19 | 71 | 95.0 (75.1–99.9) | 32.4 (23.6–42.1) | 21.1 (13.2–31.0) | 97.1 (85.1–99.9) | 1.4 (1.2–1.7) | 0.2 (0–1.1) |
≥ 3 | 17 | 43 | 85.0 (62.1–96.8) | 59.0 (49.0–68.6) | 28.3 (17.4–41.4) | 95.4 (87.1–99.0) | 2.1 (1.6–2.8) | 0.2 (0.1–0.7) |
≥ 4 | 14 | 21 | 70.0 (45.7–88.1) | 80.0 (71.1–87.2) | 40.0 (23.9–57.9) | 93.3 (86.0–97.5) | 3.5 (2.2–5.6) | 0.4 (0.2–0.7) |
≥ 5 | 11 | 8 | 55.0 (31.5–76.9) | 92.4 (85.5–96.6) | 57.9 (33.5–79.8) | 91.5 (84.5–96.0) | 7.2 (3.3–15.7) | 0.5 (0.3–0.8) |
≥ 6 | 5 | 2 | 25.0 (8.7–49.1) | 98.1 (93.3–99.8) | 71.4 (29.0–96.3) | 87.3 (79.9–92.7) | 13.1 (2.7–63.0) | 0.8 (0.6–1.0) |
Diagnostic value of PVL for identifying severe dengue
Cutoff value | The 2009 WHO definitions | Sensitivity (95 % CI) | Specificity (95 % CI) | PPV (95 % CI) | NPV (95 % CI) | LR+ (95 % CI) | LR– (95 % CI) | |
---|---|---|---|---|---|---|---|---|
Severe (n = 20) | Non-severe (n = 105) | |||||||
Lactate at admission (mmol/L) | ||||||||
≥ 1.0 mmol/L | 19 | 96 | 95.0 (75.1–99.9) | 8.6 (4.0–15.6) | 16.5 (10.2–24.6) | 90.0 (55.5–99.8) | 1.0 (0.9–1.2) | 0.6 (0.1–4.4) |
≥ 1.5 mmol/L | 18 | 51 | 90.0 (68.3–98.8) | 51.4 (41.5–61.3) | 26.1 (16.2–38.1) | 96.4 (87.7–99.6) | 1.8 (1.4–2.4) | 0.2 (0.1–0.7) |
≥ 2.0 mmol/L | 14 | 15 | 70.0 (45.7–88.1) | 85.7 (77.5– 91.8) | 48.3 (29.4–67.47) | 93.8 (86.9–97.7) | 4.9 (2.8–8.5) | 0.4 (0.2–0.7) |
≥ 2.5 mmol/L | 13 | 4 | 65.0 (40.8–84.6) | 96.2 (90.5–99.0) | 76.5 (50.1–93.2) | 93.5 (87.1–97.4) | 17.1 (6.2–47.0) | 0.4 (0.2–0.7) |
Clinical fluid accumulation and/or lactate at admission (mmol/L) | ||||||||
≥ 1.0 mmol/L | 20 | 96 | 100.0 (83.2–100.0) | 8.6 (4.0-15.6) | 17.2 (10.9–25.4) | 100.0 (66.4–100.0) | 1.1 (1.0–1.2) | 0 |
≥ 1.5 mmol/L | 20 | 55 | 100.0 (83.2–100.0) | 47.6 (37.8–57.6) | 26.7 (17.1–38.1) | 100.0 (92.9–100.0) | 1.9 (1.6–2.3) | 0 |
≥ 2.0 mmol/L | 18 | 22 | 90.0 (68.3–98.8) | 79.1 (70.0–86.4) | 45.0 (29.3–61.5) | 97.6 (91.8–99.7) | 4.3 (2.9–6.4) | 0.1 (0–0.5) |
≥ 2.5 mmol/L | 18 | 13 | 90.0 (68.3–98.8) | 87.6 (79.8–93.2) | 58.1 (39.1–75.4) | 97.9 (92.5–99.7) | 7.3 (4.3–12.3) | 0.1 (0–0.4) |